
ALLPF
Healthcare · Diagnostics & Research · $40.4M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 17, 2022 | Before the open | — | -0.01 | — |
| Apr 29, 2022 | Before the open | — | -0.01 | — |
| Feb 24, 2022 | Before the open | — | -0.02 | — |
| Nov 12, 2021 | Before the open | — | -0.02 | — |
| Aug 31, 2021 | Before the open | — | -0.02 | — |
| May 12, 2021 | Before the open | — | -0.01 | — |
| Feb 19, 2021 | Before the open | — | -0.01 | — |
| Nov 19, 2020 | Before the open | 0.00 | -0.01 | — |
| Aug 20, 2020 | Before the open | 0.00 | -0.01 | — |
| May 15, 2020 | After the close | 0.00 | -0.01 | — |
| Feb 21, 2020 | Before the open | 0.00 | -0.01 | — |
| Nov 5, 2019 | After the close | 0.00 | -0.02 | — |
| Aug 21, 2019 | After the close | 0.00 | -0.01 | — |
| Apr 12, 2019 |
AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao…
| After the close |
| 0.00 |
| -0.01 |
| — |
| Mar 31, 2019 | Time not confirmed | 0.00 | -0.01 | — |
| Dec 31, 2018 | Time not confirmed | 0.00 | -0.01 | — |
| Sep 30, 2018 | Time not confirmed | 0.00 | -0.02 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | -0.02 | — |
| Mar 31, 2018 | Time not confirmed | 0.00 | -0.02 | — |